Portal de Periódicos da CAPES

Sialic acid blockade inhibits the metastatic spread of prostate cancer to bone

2024; Elsevier BV; Volume: 104; Linguagem: Inglês

10.1016/j.ebiom.2024.105163

2352-3964

Kirsty Hodgson, Margarita Orozco‐Moreno, Emily Archer Goode, Matthew L. Fisher, Rebecca Garnham, Richard Beatson, Helen Turner, Karen Livermore, Yuhan Zhou, Laura Wilson, Eline A Visser, Johan F. A. Pijnenborg, Nienke Eerden, Sam J. Moons, Emiel Rossing, Gerald Hysenaj, Rashi Krishna, Ziqian Peng, Kyla Putri Nangkana, Edward N. Schmidt, Adam Duxfield, Ella P Dennis, Rakesh Heer, Michelle A. Lawson, Matthew S. Macauley, David J Elliott, Christian Büll, Emma Scott, Thomas J Boltje, Richard R. Drake, Ning Wang, Jennifer Munkley,

Bone health and treatments

Bone metastasis is a common consequence of advanced prostate cancer. Bisphosphonates can be used to manage symptoms, but there are currently no curative treatments available. Altered tumour cell glycosylation is a hallmark of cancer and is an important driver of a malignant phenotype. In prostate cancer, the sialyltransferase ST6GAL1 is upregulated, and studies show ST6GAL1-mediated aberrant sialylation of N-glycans promotes prostate tumour growth and disease progression.